How IDEXX Laboratories Makes its Money: Revenue Breakdown
A breakdown of IDEXX Laboratories (IDXX) financials. See how IDEXX Laboratories makes money from Companion Animal Group (CAG) Diagnostics, CAG Reference Laboratory Services, Water (Microbiology Testing), and more using their 2024 annual report.
How Does IDEXX Laboratories Make its Money?
IDEXX Laboratories is the global leader in veterinary diagnostics, providing in-clinic analyzers, reference laboratory services, rapid assay test kits, and practice management software to veterinary practices worldwide. The company dominates the companion animal (pet) diagnostics market with an estimated 50%+ global share. IDEXX’s instruments are placed in veterinary clinics under a razor-and-blade model — the company sells or leases analyzers and then generates recurring revenue from consumables, tests, and reference lab services. With pet ownership growing, vet visits increasing, and the humanization of pets driving demand for advanced diagnostics, IDEXX benefits from powerful secular tailwinds.
IDEXX’s moat is the razor-and-blade model combined with a technology lead that would take competitors years and billions to replicate. When a veterinary practice installs IDEXX’s instrument suite (ProCyte One hematology analyzer, Catalyst One chemistry analyzer, SediVue urine sediment analyzer), the clinic becomes locked into IDEXX’s consumables and reagent ecosystem — each test requires IDEXX-specific proprietary consumables. The practice’s staff trains on IDEXX interfaces, the patient records integrate into IDEXX’s PACS and software systems, and switching to a competitor (Zoetis’ Vetscan, Heska) would require ripping out instruments, retraining staff, and disrupting clinical workflows. This installed base creates highly predictable, recurring revenue that grows as clinics run more tests per visit.
IDEXX Laboratories (IDXX) Business Model
IDEXX Laboratories Competitors
IDEXX Laboratories’s key competitors and comparable public companies in the healthcare sector include Zoetis, Danaher, Thermo Fisher Scientific, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IDEXX Laboratories stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Companion Animal Group (CAG) Diagnostics | $3,200 | $2,900 | +10.3% |
| CAG Reference Laboratory Services | $1,100 | $1,000 | +10.0% |
| Water (Microbiology Testing) | $200 | $180 | +11.1% |
| Livestock, Poultry & Dairy (LPD) | $200 | $190 | +5.3% |
| Total Revenue | $3,900 | $3,700 | +5.4% |
Companion Animal Group (CAG) Diagnostics — 82% of Revenue
The core business: in-clinic diagnostic instruments and their associated consumables, rapid assay test kits, and veterinary software sold to companion animal (dogs, cats) veterinary practices. The product portfolio includes the ProCyte One (complete blood count analyzer), Catalyst One (blood chemistry analyzer), SediVue Dx (automated urinalysis), SNAP rapid assay tests (point-of-care tests for heartworm, Lyme disease, parvovirus, and other conditions), and Cornerstone/Neo practice management software. Revenue grew 10.3% in 2024.
The growth driver is increasing diagnostic utilization — vets are running more tests per clinical visit as the standard of care for pets increasingly mirrors human medicine. A decade ago, a routine wellness visit for a dog might include a basic physical exam. Today, many practices run comprehensive blood panels, urinalysis, and disease screening tests as part of routine wellness — and IDEXX’s instruments make this fast and easy to do in-clinic without sending samples to an external laboratory. IDEXX benefits from both instrument placements (expanding the installed base) and consumable volume (running more tests per instrument).
CAG Reference Laboratory Services — 28% of Revenue
IDEXX operates a network of reference laboratories across the US and internationally where veterinary practices send samples for tests that are too complex or low-volume to perform in-clinic. These include specialty diagnostics (advanced pathology, cytology, endocrinology), genetic testing, and high-throughput screening panels. Revenue grew 10.0% in 2024, driven by same-store volume growth and geographic expansion.
IDEXX’s reference lab business is complementary to its in-clinic instruments: clinics use IDEXX in-clinic analyzers for immediate results on routine tests and send specialty samples to IDEXX reference labs for advanced diagnostics. This dual-channel approach increases total IDEXX revenue per clinical visit and creates a more comprehensive relationship with each veterinary practice.
Water (Microbiology Testing) — 5% of Revenue
The leading provider of rapid microbiology testing products for water safety, used by municipal water utilities, food and beverage manufacturers, and environmental testing labs to test for coliform bacteria, E. coli, Legionella, and other pathogens. Revenue grew 11.1% in 2024. While small relative to companion animal diagnostics, the Water segment is a niche leader with defensible market share and benefits from increasing regulatory requirements for water testing globally.
Livestock, Poultry & Dairy (LPD) — 5% of Revenue
Diagnostic tests and services for livestock and poultry health, including pregnancy testing, disease surveillance, and food safety testing. Revenue grew 5.3% in 2024. This segment is smaller and slower-growing than companion animal diagnostics and is a relatively minor part of the IDEXX story.
IDEXX Laboratories (IDXX) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3,900 | $3,700 |
| Cost of Revenue | $1,600 | $1,500 |
| Gross Profit | $2,300 | $2,200 |
| Operating Expenses | $1,000 | $950 |
| Operating Income | $1,300 | $1,250 |
| Net Income | $1,000 | $950 |
All values in millions USD unless otherwise stated.
Financial data sourced from IDEXX Laboratories SEC Filings.
IDEXX Laboratories (IDXX) Key Financial Metrics
- Gross Margin: 59.0%
- Operating Margin: 33.3%
- Revenue Growth: 5.4%
Is IDEXX Laboratories Profitable?
Yes, IDEXX is highly profitable with exceptional margins for a diagnostics company. The 59.0% gross margin reflects the razor-and-blade economics — consumables and reagents carry very high margins once the instruments are placed in clinics. The 33.3% operating margin demonstrates efficient conversion of gross profit to operating income despite significant R&D spending (~10% of revenue) required to maintain the technology lead. Net income grew 5.3% to $1.0 billion on 5.4% revenue growth. IDEXX generates strong free cash flow that is deployed primarily into share buybacks — the company has reduced its share count by approximately 25% over the past decade. The 5.4% revenue growth rate is below IDEXX’s long-term trend of 8-12% organic growth, reflecting a normalization of veterinary visit volumes after a pandemic-era surge (pet adoption boomed during COVID, driving elevated vet visits in 2020-2022).
IDEXX Laboratories (IDXX): What to Watch
- Clinical visit trends and diagnostic revenue per visit — The number of companion animal clinical visits and the diagnostic revenue IDEXX earns per visit are the two fundamental growth drivers. Post-pandemic visit normalization has been a headwind, and a sustained recovery in visit growth would reaccelerate revenue.
- Premium instrument placement growth — The number of new ProCyte One, Catalyst One, and SediVue placements expands IDEXX’s installed base and locks in recurring consumable revenue. Placement rates, particularly in international markets, indicate future growth.
- International expansion — IDEXX has significant runway in Europe and Asia-Pacific, where in-clinic diagnostic utilization lags the US by many years. Expanding the international installed base is a key long-term growth lever.
- Competitive dynamics — Zoetis (Vetscan), Heska (acquired by Mars), and new entrants are investing in veterinary diagnostics. IDEXX’s technology lead and installed base switching costs provide protection, but competitive pressure on pricing and instrument placement is increasing.
- Software and data ecosystem — IDEXX’s practice management software (Cornerstone, Neo), PACS imaging, and cloud-based analytics create an integrated ecosystem. Deeper software adoption increases switching costs and provides a data advantage for developing AI-assisted diagnostic tools.
IDEXX Laboratories (IDXX) Financial Summary
IDEXX Laboratories dominates companion animal diagnostics with 50%+ global market share, leveraging a razor-and-blade model where proprietary instruments placed in veterinary clinics generate highly recurring consumable and test revenue. Revenue grew 5.4% to $3.9 billion in 2024, with CAG Diagnostics (82% of revenue) growing 10.3% as vets run more tests per visit and the installed base expands. The 59.0% gross margin and 33.3% operating margin reflect the premium economics of a diagnostics business with high switching costs and minimal price sensitivity. Net income grew to $1.0 billion. The growth story is about diagnostic utilization — as veterinary medicine increasingly mirrors human healthcare standards, pets get more blood tests, more imaging, and more disease screening at every visit, and IDEXX captures a growing share of that diagnostic spending.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.